Giant-Cell Arteritis Market in 7MM is expected to witness a major change in the study period 2019-2032

The Giant-Cell Arteritis market report provides current treatment practices, emerging drugs, Giant-Cell Arteritis market share of the individual therapies, and current and forecasted Giant-Cell Arteritis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Giant-Cell Arteritis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Giant-Cell Arteritis market.

Key takeaways from Giant-Cell Arteritis Market Research Report
• Estimates show that the highest cases of GCA in the 7MM were in United States, followed by the United Kingdom, France, Italy, Germany, Spain, and Japan in 2020.
• In the United States, the total number of prevalent cases of Giant Cell Arteritis was 244,438 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
• In the year 2020, the total prevalent cases of Giant Cell Arteritis were 190,573 cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.
• In Japan, the total number of prevalent cases of Giant Cell Arteritis was 875 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.

For further information on the market impact by therapies, download the Giant-Cell Arteritis sample, click here for Giant-Cell Arteritis Market Size @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Giant Cell Arteritis Overview
Giant Cell Arteritis (GCA) is a systemic inflammatory vasculitis of unknown etiology that occurs in older persons and can result in a wide variety of systemic, neurologic, and ophthalmologic complications. GCA is one of the most common forms of systemic vasculitis in adults. Other names of GCA include arteritis cranialis, Horton disease, granulomatous arteritis, and arteritis of the aged. The term "Giant cell Arteritis" is often used because when one looks at biopsies of the inflamed temporal arteries under a microscope, one often sees large or "giant" cells.

Giant Cell Arteritis Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Giant Cell Arteritis
• Total subtype-specific cases of Giant Cell Arteritis
• Total Age group-specific Cases of Giant Cell Arteritis
• Total Clinical Manifestation-specific Cases of Giant Cell Arteritis
• Total Treated Cases of Giant Cell Arteritis

Keen to learn how Giant Cell Arteritis Market Trends are going to appear in 2032 for the 7MM, Download Giant Cell Arteritis Market Outlook @ https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Giant Cell Arteritis Emerging Drugs

Rinvoq (upadacitinib), (Abbvie)
Rinvoq (upadacitinib) is an orally administered selective and reversible JAK inhibitor, pro-inflammatory cytokines use immune signaling networks, such as the JAK-STAT pathway, to communicate with the cell nucleus. When dysregulated, these signals increase the inflammatory response, leading to cycles of chronic inflammation, presenting as pain, swelling, and progressive joint destruction. It is approved in the United States, Japan and the European Union. Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs), is being developed by Abbvie. Currently, upadacitinib is in the Phase III stage of clinical development for the Giant Cell Arteritis (GCA).

Cosentyx (secukinumab), (Novartis Pharmaceuticals)
Cosentyx (secukinumab) is an injectable fully human monoclonal antibody that specifically inhibits interleukin-17A (IL-17A), a cytokine involved in several immunological diseases, is being developed by Novartis Pharmaceuticals. Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. The company has completed one Phase II study, and it is currently in the Phase III stage of clinical development for the treatment of Giant Cell Arteritis.

KPL-301 (mavrilimumab), (CSL/Kiniksa Pharmaceuticals)
KPL-301 is a subcutaneous fully-human monoclonal antibody that antagonizes GM-CSF signaling by binding to the alpha subunit of the GM-CSF receptor is being developed by CSL and Kiniksa Pharmaceuticals for the treatment of Giant cell arteritis (GCA), a chronic inflammatory disease of medium-large blood vessel. KPL-301 is designed to targets granulocyte macrophage colony-stimulating factor receptor alpha (GM-CSFRα) and inhibits the signaling of granulocyte macrophage colony-stimulating factor (GM-CSF). Currently Kiniksa Pharmaceuticals is also evaluating mavrilimumab for the potential treatment of severe coronavirus 2019 disease, or COVID-19, pneumonia and hyper inflammation. Kiniksa Pharmaceuticals has completed Phase II, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in Giant Cell Arteritis, the trial has enrolled 70 participants.

Tremfya (guselkumab), (Johnson & Johnson/MorphoSys AG)
Tremfya (guselkumab) is an Intravenous and Subcutaneous administered monoclonal antibody that selectively targets IL-23 and is the first-in-class selective IL-23 inhibitor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses, approved to treat moderate-to-severe plaque psoriasis, and is being developed by Johnson & Johnson utilizing MorphoSys's HuCAL (Human Combinatorial Antibody Library) technology. Tremfya is currently in the Phase II stage of clinical development for the Giant Cell Arteritis (GCA). The study (NCT04633447) has been initiated and started recruiting participants.

Giant Cell Arteritis Market Outlook
Several factors which are understood till now may include genetic factors (HLA family), infectious or environmental factors, immune responses, and T-cell activation. The symptoms mainly include constitutional symptoms (weight loss, fever, fatigue, anorexia, and malaise), headache, jaw claudication, visual symptoms, polymyalgia rheumatica, neurological symptoms, respiratory symptoms, and extracranial symptoms. Giant cell arteritis involves some serious complications if not treated early can also hamper a patient's quality of life. Some serious complications may involve blindness, aortic aneurysm, ischemic stroke, heart attack, and peripheral artery disease.

Know more about the driving forces and restraining factors, click here for Giant Cell Arteritis Market Companies @ https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Giant Cell Arteritis Market Report
• Coverage- 7MM
• Giant Cell Arteritis Companies- Roche Holding, AbbVie, Novartis Pharmaceuticals, CSL/Kiniksa Pharmaceuticals, Johnson & Johnson/MorphoSys AG, and others.
• Giant Cell Arteritis Pipeline Therapies- Rinvoq (upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya (guselkumab), and others.
• Giant Cell Arteritis Market Dynamics: Giant Cell Arteritis Market Drivers and Barriers
• Giant Cell Arteritis Unmet Needs, Access and Reimbursement

Table of Content
1. Key Insights
2. Giant-Cell Arteritis Executive Summary
3. Giant-Cell Arteritis Competitive Intelligence Analysis
4. Giant-Cell Arteritis: Market Overview at a Glance
5. Giant-Cell Arteritis: Disease Background and Overview
6. Patient Journey
7. Giant-Cell Arteritis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Giant-Cell Arteritis Unmet Needs
10. Key Endpoints of Giant-Cell Arteritis Treatment
11. Giant-Cell Arteritis Marketed Products
12. Giant-Cell Arteritis Emerging Therapies
13. Giant-Cell Arteritis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Giant-Cell Arteritis Market Outlook
16. Access and Reimbursement Overview of Giant-Cell Arteritis
17. KOL Views
18. Giant-Cell Arteritis Market Drivers
19. Giant-Cell Arteritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Interested in knowing the Giant-Cell Arteritis market by 2032? Click to get a snapshot of the Giant-Cell Arteritis Market Research Report @ https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trending Market Research Reports

CAR-T Pipeline @ https://www.delveinsight.com/report-store/car-t-pipeline-insight

Stem Cell Market @ https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market @ https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Blastomycosis market @ https://www.delveinsight.com/report-store/blastomycosis-market

Oncolytic virus cancer therapy pipeline @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Superficial punctate keratitis @ https://www.delveinsight.com/report-store/superficial-punctate-keratitis-market

Persistent corneal epithelial defects market @ https://www.delveinsight.com/report-store/persistent-epithelial-defect-market

Ranibizumab biosimilar insights @ https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight

Brucellosis market @ https://www.delveinsight.com/report-store/brucellosis-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.